Although more research is needed to fully understand the efficacy and safety of BRD4 inhibitors in treating PAH and to identify the optimal dosing and treatment duration, promising preclinical and clinical trial results suggest that BRD4 inhibitors could potentially serve as novel and effective treatment strategies for PAH. This evidence concerns the gene BRD4 and pulmonary arterial hypertension.